United Therapeutics Stock Investor Sentiment

UTHR Stock  USD 307.24  1.85  0.61%   
Slightly above 56% of all United Therapeutics' retail investors are looking to take a long position. The analysis of the overall investor sentiment regarding United Therapeutics suggests that some traders are interested. United Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in United Therapeutics. Many technical investors use United Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.

Comfort Level 56

 Interested

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use United Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward United Therapeutics.

United Historical Sentiment

Although United Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding United, such as negative comments on social media and news outlets, may cause fear in the market and push United Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of United.
  

United Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards United Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

United Therapeutics Historical Investor Sentiment

Investor biases related to United Therapeutics' public news can be used to forecast risks associated with an investment in United. The trend in average sentiment can be used to explain how an investor holding United can time the market purely based on public headlines and social activities around United Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
United Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for United Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average United Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on United Therapeutics.

United Therapeutics Maximum Pain Price Across June 20th 2025 Option Contracts

United Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of United Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of United Therapeutics' options.
over a month ago at independent.co.uk         
New Hampshire man is 2nd person known to be living with a pig kidney
news
over a month ago at cnn.com         
Experimental transplants with organs from gene-edited pigs see major steps forward
CNN News
over a month ago at nypost.com         
New Hampshire man who was ready to fight becomes second know person living with pig kidney
news
over a month ago at thelincolnianonline.com         
Disposition of 7700 shares by Mahon Paul A of United Therapeutics at 163.3 subject to Rule 16b-3
news
over a month ago at sciencealert.com         
Pig Kidney Transplant Trials Given FDA Approval in The US
news
over a month ago at gurufocus.com         
State Street Corp Reduces Stake in United Therapeutics Corp
Gurufocus Stories at Macroaxis
over a month ago at simplywall.st         
Is United Therapeutics Using Too Much Debt?
Simply Wall St News at Macroaxis
over a month ago at gurufocus.com         
United Therapeutics Corp Completes Enrollment for TETON 1
Gurufocus Stories at Macroaxis
over a month ago at statnews.com         
Mercks 2025 guidance hit by Gardasil pause in China
news
over a month ago at bizjournals.com         
United Therapeutics scores FDA go-ahead for pig organ transplant clinical trial
bizjournals News
over a month ago at finance.yahoo.com         
United Therapeutics Corporations Fundamentals Look Pretty Strong Could The Market Be Wrong About The...
Yahoo News
over a month ago at upi.com         
FDA OKs clinical trials for pig kidney transplants in people
news
over a month ago at businesswire.com         
United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostin...
businesswire News
over a month ago at finance.yahoo.com         
FDA Greenlights Studies of Pig Kidney Transplants in Humans
Yahoo News
over a month ago at finance.yahoo.com         
eMerge Americas 2025 Announces Dynamic Speaker Lineup, including Dave Portnoy, Palmer Luckey, Armand...
Yahoo News
Far too much social signal, news, headlines, and media speculation about United Therapeutics that are available to investors today. That information is available publicly through United media outlets and privately through word of mouth or via United internal channels. However, regardless of the origin, that massive amount of United data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of United Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of United Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to United Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive United Therapeutics alpha.

United Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 15000 shares by Sullivan Louis W of United Therapeutics at 175.43 subject to Rule 16b-3
12/18/2024
2
Disposition of 1851 shares by Sullivan Louis W of United Therapeutics subject to Rule 16b-3
12/19/2024
3
Disposition of 2500 shares by Michael Benkowitz of United Therapeutics at 111.0 subject to Rule 16b-3
12/26/2024
4
Disposition of 7700 shares by Mahon Paul A of United Therapeutics at 163.3 subject to Rule 16b-3
01/02/2025
5
Disposition of 600 shares by Michael Benkowitz of United Therapeutics at 367.8917 subject to Rule 16b-3
01/13/2025
6
Disposition of 100 shares by Michael Benkowitz of United Therapeutics at 375.22 subject to Rule 16b-3
01/27/2025
7
FDA OKs clinical trials for pig kidney transplants in people
02/04/2025
8
Disposition of 1142 shares by Michael Benkowitz of United Therapeutics at 345.6904 subject to Rule 16b-3
02/11/2025
9
Strength Seen in United Therapeutics Can Its 4.9 percent Jump Turn into More Strength
02/13/2025
10
Disposition of 196 shares by Michael Benkowitz of United Therapeutics at 360.8488 subject to Rule 16b-3
02/14/2025
11
Disposition of 400 shares by Michael Benkowitz of United Therapeutics at 373.6725 subject to Rule 16b-3
02/18/2025
12
Ieq Capital LLC Buys 5,171 Shares of United Therapeutics Co.
02/24/2025
13
United Therapeutics Shares Drop After Disappointing Earnings
02/26/2025
14
United Therapeutics Shares Gap Down Following Insider Selling
02/27/2025
15
Disposition of 2500 shares by Thompson Tommy G of United Therapeutics at 175.43 subject to Rule 16b-3
02/28/2025
16
Disposition of 137 shares by Michael Benkowitz of United Therapeutics at 318.8211 subject to Rule 16b-3
03/03/2025
17
Disposition of 7179 shares by Michael Benkowitz of United Therapeutics at 111.0 subject to Rule 16b-3
03/04/2025
18
Disposition of 6550 shares by Mahon Paul A of United Therapeutics at 163.3 subject to Rule 16b-3
03/06/2025
19
Andra AP fonden Purchases 5,500 Shares of United Therapeutics Co.
03/07/2025
20
Disposition of 2000 shares by Michael Benkowitz of United Therapeutics at 111.0 subject to Rule 16b-3
03/10/2025
21
Disposition of 1520 shares by Michael Benkowitz of United Therapeutics at 360.7233 subject to Rule 16b-3
03/13/2025

Additional Tools for United Stock Analysis

When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.